| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 922 | 2008 |
| Once-weekly dalbavancin versus daily conventional therapy for skin infection HW Boucher, M Wilcox, GH Talbot, S Puttagunta, AF Das, MW Dunne New England Journal of Medicine 370 (23), 2169-2179, 2014 | 494 | 2014 |
| Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial CM O’Connor, MW Dunne, MA Pfeffer, JB Muhlestein, L Yao, S Gupta, ... JAMA 290 (11), 1459-1466, 2003 | 432* | 2003 |
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ... New England Journal of Medicine 359 (14), 1442-1455, 2008 | 429 | 2008 |
| Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both DV Havlir, MP Dubé, FR Sattler, DN Forthal, CA Kemper, MW Dunne, ... New England Journal of Medicine 335 (6), 392-398, 1996 | 428 | 1996 |
| A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection MW Dunne, S Puttagunta, P Giordano, D Krievins, M Zelasky, ... Clinical Infectious Diseases 62 (5), 545-551, 2016 | 237 | 2016 |
| Extended duration dosing and distribution of dalbavancin into bone and articular tissue MW Dunne, S Puttagunta, CR Sprenger, C Rubino, S Van Wart, ... Antimicrobial agents and chemotherapy 59, 1849-1855, 2015 | 221 | 2015 |
| In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin ABS Sidhu, Q Sun, LJ Nkrumah, MW Dunne, JC Sacchettini, DA Fidock Journal of Biological Chemistry 282 (4), 2494-2504, 2007 | 194 | 2007 |
| Plasmodium vivax clinically resistant to chloroquine in Colombia. J Soto, J Toledo, P Gutierrez, M Luzz, N Llinas, N Cedeno, M Dunne, ... The American journal of tropical medicine and hygiene 65 (2), 90-93, 2001 | 174 | 2001 |
| Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety U Rappo, S Puttagunta, V Shevchenko, A Shevchenko, A Jandourek, ... Open forum infectious diseases 6 (1), ofy331, 2019 | 173 | 2019 |
| Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Ken SL Andersen, AJ Oloo, DM Gordon, OB Ragama, GM Aleman, JD Berman, ... Clinical infectious diseases 26 (1), 146-150, 1998 | 172 | 1998 |
| A Multicenter Study of Azithromycin, Alone and in Combination with Chloroquine, for the Treatment of Acute Uncomplicated Plasmodium falciparum Malaria in India MW Dunne, N Singh, M Shukla, N Valecha, PC Bhattacharyya, V Dev, ... Journal of Infectious Diseases 191 (10), 1582-1588, 2005 | 119 | 2005 |
| Once Weekly Azithromycin Therapy for Prevention of Mycobacterium avium Complex Infection in Patients with AIDS: A Randomized, Double-Blind, Placebo … EC Oldfield III, WJ Fessel, MW Dunne, G Dickinson, MR Wallace, W Byrne, ... Clinical infectious diseases 26 (3), 611-619, 1998 | 105 | 1998 |
| Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS DV Havlir, MP Dubé, JA McCutchan, DN Forthal, CA Kemper, MW Dunne, ... Clinical infectious diseases 27 (6), 1369-1375, 1998 | 99 | 1998 |
| A Randomized, Double-Blind Trial Comparing Azithromycin and Clarithromycin in the Treatment of Disseminated Mycobacterium avium Infection in Patients with … M Dunne, J Fessel, P Kumar, G Dickenson, P Keiser, M Boulos, ... Clinical infectious diseases 31 (5), 1245-1252, 2000 | 98 | 2000 |
| Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models D Girard, SM Finegan, MW Dunne, ME Lame Journal of Antimicrobial Chemotherapy 56 (2), 365-371, 2005 | 95 | 2005 |
| Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin … MW Dunne The Journal of infectious diseases 181 (Supplement_3), S527-S578, 2000 | 92 | 2000 |
| “One-size-fits-all”? Optimizing treatment duration for bacterial infections P Geli, R Laxminarayan, M Dunne, DL Smith PloS one 7 (1), e29838, 2012 | 89 | 2012 |
| Prophylaxis of Plasmodium falciparum Malaria with Azithromycin Administered to Volunteers SL Anderson, J Berman, R Kuschner, D Wesche, A Magill, B Wellde, ... Annals of internal medicine 123 (10), 771-773, 1995 | 87 | 1995 |
| Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies MW Dunne, GH Talbot, HW Boucher, M Wilcox, S Puttagunta Drug safety 39, 147-157, 2016 | 81 | 2016 |
David FidockProfessor of Microbiology & Immunology and of Medical Sciences (in Medicine), Columbia University在 columbia.edu 的电子邮件经过验证
